Welcome to our dedicated page for BioRestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on BioRestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a cutting-edge biotechnology company based in the United States, dedicated to developing regenerative medicine products and therapies using cell and tissue protocols, particularly involving adult stem cells. The company’s core focuses are its Disc/Spine Program and Metabolic Program.
In the Disc/Spine Program, their lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. This innovative treatment is designed for the non-surgical management of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRTX-100 undergoes a meticulous production process, starting from the collection of a patient’s bone marrow, followed by the isolation and culturing of stem cells, and finally cryopreserving these cells. The therapy involves injecting BRTX-100 into the patient's damaged disc, offering hope for patients whose pain has not been alleviated by other non-invasive treatments.
The Metabolic Program focuses on developing cell-based therapies to combat obesity and metabolic disorders using brown adipose-derived stem cells. This innovative approach aims to generate brown adipose tissue to help address these widespread health issues.
BioRestorative Therapies is also venturing into the rapidly growing bio-cosmeceutical market. The company recently signed a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, a prominent North American aesthetics company. This partnership aims to introduce proprietary cell-based innovations to the aesthetics market, leveraging both BioRestorative’s expertise in cell-based biologics and Cartessa’s strong market presence.
Financially, BioRestorative is strong, ending 2023 with around $11.1 million in cash and cash equivalents, and an additional $7.6 million from a recent private placement. This solid financial standing, combined with expected revenues from its new commercial products, allows the company to pursue further advancements in their clinical and preclinical pipelines, including their BRTX-100 and ThermoStem® programs.
For more information, visit BioRestorative Therapies or contact Investor Relations at ir@biorestorative.com.
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, has announced it will release its second quarter 2024 financial results after market close on Tuesday, August 13, 2024. Following the announcement, the company's management will host a conference call to review the financial results and provide a business update.
The conference call details are as follows:
- Date: Tuesday, August 13, 2024
- Time: 4:30 p.m. ET
- Domestic: 1-877-545-0523
- International: 1-973-528-0016
- Access Code: 151026
BioRestorative Therapies (NASDAQ:BRTX) announced that its Chief Scientist and VP of R&D, Francisco Silva, has been appointed Section Editor of the new Regenerative Medicine section in the Journal of Translational Medicine. This prestigious journal ranks among the top 3% worldwide with a 2021 impact factor of 8.440. Silva, who leads BRTX's cell-based therapeutics development, is currently the principal investigator for a Phase 2 study of BRTX-100 in treating chronic lumbar disc disease. He also pioneered the development of an artificial 3D brown adipose transplant using human brown adipose stem cells for the company's ThermoStem® program. Silva's appointment highlights BRTX's growing prominence in regenerative medicine research and development.
BioRestorative Therapies (NASDAQ:BRTX) has received a notice of allowance from the Japanese Patent Office for its ThermoStem® platform patent application. The patent covers a method of creating 3D brown adipose derived stem cell aggregates without differentiation medium. This complements their existing patent portfolio and supports potential licensing opportunities. Preclinical studies conducted with the University of Utah School of Medicine showed that ThermoStem® can reduce weight, triglyceride, and blood glucose levels in mice, mirroring the effects of GLP1 drugs. Substantive licensing discussions are ongoing with a commercial stage regenerative medicine company.
BioRestorative Therapies (NASDAQ: BRTX) has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Quarterly Report on Form 10-Q for Q1 2024. The clinical-stage company focusing on stem cell therapies reported a significant year-over-year improvement in operating performance. For the quarter ending March 31, 2024, BRTX reported a loss from operations of $4.1 million, a 29% reduction from the $5.8 million loss in Q1 2023. The net loss for Q1 2024 was $2.2 million, or $0.33 per share, compared to $7.2 million, or $1.93 per share, in Q1 2023. Cash used in operating activities was $2.3 million, slightly less than the $2.4 million used in Q1 2023. BioRestorative ended the quarter with $16.4 million in cash, cash equivalents, and marketable securities.
BioRestorative Therapies (NASDAQ:BRTX) is in substantive discussions for a potential license agreement regarding its ThermoStem® metabolic disease program with an undisclosed regenerative medicine company.
ThermoStem® leverages brown adipose derived stem cells (BADSCs) to treat obesity and metabolic disorders.
Preclinical studies with the University of Utah demonstrated significant weight, triglyceride, and blood glucose reductions in mice.
The platform is supported by a comprehensive patent portfolio covering both U.S. and international markets.
While these discussions signal strong interest, no guarantees exist that a deal will be finalized.
BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage company specializing in stem cell-based therapies, announced that CEO Lance Alstodt will attend the Jefferies Global Healthcare Conference from June 5-6, 2024, at the Marriot Marquis in New York. The company will also hold one-on-one meetings with investors during the event.
BioRestorative Therapies (NASDAQ:BRTX) received a non-compliance notice from Nasdaq for not filing its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, on time. The notice was issued by Nasdaq's Listing Qualifications Department, highlighting a breach of Listing Rule 5250(c)(1), which mandates timely filing of all required periodic reports with the SEC.
The company has until July 22, 2024, to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 days from the original filing due date to regain compliance, potentially extending the deadline to November 18, 2024. The company’s securities will continue to trade on Nasdaq under the symbol 'BRTX.' BioRestorative is making efforts to complete and file the Form 10-Q as soon as possible. This announcement follows Nasdaq's Listing Rule 5810(b), which requires immediate disclosure of such notifications.
BioRestorative Therapies (NASDAQ:BRTX) has entered into a five-year exclusive supply agreement with Cartessa Aesthetics to provide cell-based biologics, targeting the growing aesthetics market. The global aesthetics market, valued at $75.46 billion in 2023, is expected to reach $232.49 billion by 2032. BioRestorative's product, Chronos ExoCR, aims to reduce fine lines and wrinkles, leveraging the company's cell biology expertise and proprietary manufacturing processes. The agreement is expected to generate meaningful revenues and reduce reliance on capital markets. BioRestorative also aims for FDA approval of its bio-cosmeceuticals.
BioRestorative Therapies (NASDAQ: BRTX) provided an update on its first quarter 2024 business performance. Key achievements include advancing its lead clinical program, BRTX-100, with promising preliminary results from a Phase 2 trial, and expanding its preclinical ThermoStem® program targeting obesity. The company secured a commercial agreement with Cartessa Aesthetics for its BioCosmeceuticals line, expected to drive significant revenue growth. Financially, BioRestorative holds $16.4 million in cash and equivalents, offering robust financial flexibility to support its initiatives.
BioRestorative Therapies, Inc. announced the development of an exosome-based biologic program targeting obesity. The candidate aims to complement FDA-approved weight loss drugs, with DMF submission and human studies planned for 2024. The ThermoStem® platform showed promising results in preclinical studies, potentially leading to big pharma partnerships.
FAQ
What is the current stock price of BioRestorative Therapies (BRTX)?
What is the market cap of BioRestorative Therapies (BRTX)?
What does BioRestorative Therapies, Inc. specialize in?
What are the main programs developed by BioRestorative Therapies?
What is BRTX-100?
How does BRTX-100 work?
What recent partnership has BioRestorative Therapies entered into?
How financially stable is BioRestorative Therapies?
What are the potential benefits of the partnership with Cartessa Aesthetics?
What is the focus of BioRestorative's Metabolic Program?
Who can I contact for investor relations at BioRestorative Therapies?
Where can I find more information about BioRestorative Therapies?
